Ageing and Parkinson's disease: substantia nigra regional selectivity.

The micro-architecture of the substantia nigra was studied in control cases of varying age and patients with parkinsonism. A single 7 mu section stained with haematoxylin and eosin was examined at a specific level within the caudal nigra using strict criteria. The pars compacta was divided into a ventral and a dorsal tier, and each tier was further subdivided into 3 regions. In 36 control cases there was a linear fallout of pigmented neurons with advancing age in the pars compacta of the caudal substantia nigra at a rate of 4.7% per decade. Regionally, the lateral ventral tier was relatively spared (2.1% loss per decade) compared with the medial ventral tier (5.4%) and the dorsal tier (6.9%). In 20 Parkinson's disease (PD) cases of varying disease duration there was an exponential loss of pigmented neurons with a 45% loss in the first decade. Regionally, the pattern was opposite to ageing. Loss was greatest in the lateral ventral tier (average loss 91%) followed by the medial ventral tier (71%) and the dorsal tier (56%). The presymptomatic phase of PD from the onset of neuronal loss was estimated to be about 5 yrs. This phase is represented by incidental Lewy body cases: individuals who die without clinical signs of PD or dementia, but who are found to have Lewy bodies at post-mortem. In 7 cases cell loss was confined to the lateral ventral tier (average loss 52%) congruent with the lateral ventral selectivity of symptomatic PD. It was calculated that at the onset of symptoms there was a 68% cell loss in the lateral ventral tier and a 48% loss in the caudal nigra as a whole. The regional selectivity of PD is relatively specific. In 15 cases of striatonigral degeneration the distribution of cell loss was similar, but the loss in the dorsal tier was greater than PD by 21%. In 14 cases of Steele-Richardson-Olszewski syndrome (SRO) there was no predilection for the lateral ventral tier, but a tendency to involve the medial nigra and spare the lateral. These findings suggest that age-related attrition of pigmented nigral cells is not an important factor in the pathogenesis of PD.

[1]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[2]  L. Thal,et al.  The Lewy body variant of Alzheimer's disease , 1990, Neurology.

[3]  W. Gibb,et al.  The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. , 1990, Advances in neurology.

[4]  Y. Agid,et al.  Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.

[5]  W. Weiner,et al.  Could Parkinson's disease follow intra-uterine influenza? A speculative hypothesis. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[6]  A. Graybiel,et al.  Neuroleptic-sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  O. Hornykiewicz,et al.  The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease , 1988, Neuroscience Letters.

[8]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[9]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[10]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[11]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[12]  D. German,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? , 1988, Neuroscience.

[13]  C. Gerfen,et al.  The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  Schoenberg Bs.  Descriptive epidemiology of Parkinson's disease: disease distribution and hypothesis formulation. , 1987 .

[15]  A. Barbeau,et al.  Environmental and genetic factors in the etiology of Parkinson's disease. , 1987, Advances in neurology.

[16]  A. Eisen,et al.  ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AND MOTONEURONE DISEASE: ABIOTROPIC INTERACTION BETWEEN AGEING AND ENVIRONMENT? , 1986, The Lancet.

[17]  K. Nair,et al.  Progressive supranuclear palsy. , 1986, The Journal of the Association of Physicians of India.

[18]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[19]  C. Gerfen,et al.  The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[21]  P. Yates,et al.  Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. , 1984, Clinical neuropathology.

[22]  A. Barbeau.  Etiology of Parkinson’s Disease: A Research Strategy , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[23]  A. Parent,et al.  The subcortical afferents to caudate nucleus and putamen in primate: A fluorescence retrograde double labeling study , 1983, Neuroscience.

[24]  David M. A. Mann,et al.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease , 1983, Mechanisms of Ageing and Development.

[25]  Apostolos P. Georgopoulos,et al.  Cortico-basal ganglia relations and coding of motor performance , 1983 .

[26]  Marsden Cd.  Neuromelanin and Parkinson's disease. , 1983 .

[27]  R Bannister,et al.  Laryngeal abductor paralysis in multiple system atrophy. A report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. , 1981, Brain : a journal of neurology.

[28]  E V Evarts,et al.  Reaction time in Parkinson's disease. , 1981, Brain : a journal of neurology.

[29]  J. Szabo.  Organization of the ascending striatal afferents in monkeys , 1980, The Journal of comparative neurology.

[30]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[31]  J. Sung,et al.  PATHOLOGY OF SHY‐DRAGER SYNDROME* , 1978, Journal of neuropathology and experimental neurology.

[32]  Edward V. Evarts,et al.  PATHOPHYSIOLOGY OF MOTOR PERFORMANCE IN PARKINSON'S DISEASE , 1979 .

[33]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[34]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[35]  R. Lee,et al.  Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients , 1975, Brain Research.

[36]  F. Buonanno,et al.  Striato-nigral degeneration Report of a case with an unusually short course and multiple system degenerations , 1975, Journal of the Neurological Sciences.

[37]  H. Künzle.  Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study inMacaca fascicularis , 1975, Brain Research.

[38]  L. J. Rubinstein,et al.  The striatonigral degenerations. Putaminal pigments and nosology. , 1975, Brain : a journal of neurology.

[39]  J. Trotter.  Striatonigral degeneration, Alzheimer's disease, and inflammatory changes , 1973, Neurology.

[40]  J. Sharpe,et al.  Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. , 1973, Journal of the neurological sciences.

[41]  K. Fuxe,et al.  Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats. , 1972, Brain research.

[42]  A. Rajput,et al.  Striatonigral degeneration response to levodopa therapy. , 1972, Journal of the neurological sciences.

[43]  M B Carpenter,et al.  Nigrostriatal and nigrothalamic fibers in the rhesus monkey , 1972, The Journal of comparative neurology.

[44]  R. Terry,et al.  Striatonigral degeneration. Clinical-pathological correlations and response to stereotaxic surgery. , 1970, Archives of neurology.

[45]  L. Forno,et al.  CONCENTRIC HYALIN INTRANEURONAL INCLUSIONS OF LEWY TYPE IN THE BRAINS OF ELDERLY PERSONS (50 INCIDENTAL CASES): RELATIONSHIP TO PARKINSONISM , 1969, Journal of the American Geriatrics Society.

[46]  [Histochemical study on the regressive degeneration of the senile brain, with special reference to the aging of the substantia nigra]. , 1968, Shinkei kenkyu no shimpo. Advances in neurological sciences.

[47]  R. Duvoisin,et al.  ENCEPHALITIS AND PARKINSONISM. , 1965, Archives of neurology.

[48]  J. Olszewski,et al.  Cytoarchitecture of the Human Brain Stem , 1955 .

[49]  C. F. Hodge.  Changes in Ganglion Cells from Birth to Senile Death. Observations on Man and Honey‐Bee , 1894, The Journal of physiology.